Arbutus Biopharma Corporation
Clinical trials sponsored by Arbutus Biopharma Corporation, explained in plain language.
-
New pill aims to control hepatitis b in early trial
Disease control CompletedThis early-phase study tested a new oral drug called AB-101 in 128 people, including healthy volunteers and patients with chronic hepatitis B. The main goal was to check safety and how the body processes the drug. It is not a cure, but a step toward better disease control.
Phase: PHASE1 • Sponsor: Arbutus Biopharma Corporation • Aim: Disease control
Last updated May 17, 2026 11:53 UTC
-
New combo therapy may help some hepatitis b patients stop daily pills
Disease control CompletedThis study tested a new drug called AB-729 combined with standard antiviral therapy and short courses of pegylated interferon in 43 adults with chronic hepatitis B. The goal was to see if the combination is safe and can lower hepatitis B surface antigen levels enough that patient…
Phase: PHASE2 • Sponsor: Arbutus Biopharma Corporation • Aim: Disease control
Last updated May 17, 2026 11:35 UTC